Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/062999external-prioritypatent/WO2013067141A1/en
Application filed by Sanofi Sa, Exelixis IncfiledCriticalSanofi Sa
Publication of TN2014000184A1publicationCriticalpatent/TN2014000184A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Methods are provided for treating breast cancer to a patient in need of such treatment, comprising administering a compound of formula la as described herein.
TNP2014000184A2011-12-082014-04-30N- (3- { [ (3- { [2-chloro-5- (methoxy) phenyl] amino} quinoxalin- 2 -yl) amino] sulfonyl} phe nyl) - 2 -methylalaninamide as phosphatidylinositol 3 - kinase inhibitor for the treatment of lymphoproliferative malignancies
TN2014000184A1
(en)